Pepsin as a causal agent of inflammation during nonacidic reflux
OTOLARYNGOLOGY-HEAD AND NECK SURGERY
Authors: Samuels, Tina L.; Johnston, Nikki
Abstract
OBJECTIVE: To investigate the contribution of pepsin to inflammation attributed to nonacidic gastric reflux via analysis of inflammatory cytokine and cytokine receptor gene expression in pepsin-treated human hypopharyngeal epithelial cells in vitro STUDY DESIGN: Translational research. SETTING: This study was performed in an academic research laboratory SUBJECTS AND METHODS: Human hypopharyngeal epithelial cells were incubated with or Without pepsin (0.1 mg/mL) at pH 7 4. 37 degrees C, overnight. Expression of 84 inflammatory cytokines and cytokine receptors was analyzed via RT2 qPCR array RESULTS: Expression of a number of inflammatory cytokines and receptors was altered in human hypopharyngeal epithelial cells following overnight treatment with pepsin at neutral pH Greater than 1.5-fold change in gene expression was detected for CCL20. CCL26. IL8. IL1F10. ILIA, IL5, BCL6, CCR6, and CXCL14 (P < 0 05). CONCLUSION: Exposure of hypopharyngeal cells to pepsin in a nonacidic environment induces the expression of several proinflammatory cytokines and receptors. including those known to be involved in inflammation of esophageal epithelium in response to reflux and which contribute to the pathophysiology of reflux esophagitis. These data indicate that refluxed pepsin may contribute to laryngeal inflammation associated with nonacidic gastric reflux, including that experienced by patients despite maximal acid suppression therapy (C) 2009 American Academy of Otolaryngology-Head and Neck Surgery Foundation. All rights reserved.
Interleukin-38 Exerts Antiinflammatory Functions and Is Associated With Disease Activity in Systemic Lupus Erythematosus
ARTHRITIS & RHEUMATOLOGY
Authors: Rudloff, Ina; Godsell, Jack; Nold-Petry, Claudia A.; Harris, James; Hoi, Alberta; Morand, Eric F.; Nold, Marcel F.
Abstract
Objective. Knowledge of interleukin-38 (IL-38), formerly IL-1 family member 10, is sparse, but Il1f10 polymorphisms are associated with inflammatory diseases, and recombinant IL-38 inhibits inflammatory responses similar to those reported in the context of systemic lupus erythematosus (SLE). We undertook this study to explore the function of endogenous IL-38 in human peripheral blood mononuclear cells (PBMCs) as well as its abundance in serum in a well-characterized cohort of SLE patients. Methods. Serum IL-38 and IL-10 levels were quantified by enzyme-linked immunosorbent assay in 142 SLE patients at <= 3 consecutive visits and in 28 healthy volunteers. To assess IL-38 function, we silenced IL-38 in PBMCs from healthy donors using IL-38 small interfering RNA (siRNA). Results. IL-38 (63-5,928 pg/ml) was detectable in 16% of 372 serum samples. IL-38 abundance was significantly higher in samples from SLE patients than in samples from healthy controls (P=0.004) and 11-fold higher in patients with active disease (SLE Disease Activity Index 2000 [SLEDAI-2K] score of >= 4) than in those with inactive disease (SLEDAI-2K score of <4) (P=0.044). Importantly, IL-38 detection was associated with increased risk of renal lupus (relative risk [RR] 1.6, P=0.027) and central nervous system lupus (RR 2.3, P=0.034), and detectable baseline IL-38 entailed a 1.6-fold increased risk of subsequently meeting criteria for persistently active disease (P=0.0097). Longitudinal time-adjusted mean IL-38 concentration was also 6-fold higher in patients with persistently active disease than in those without (P=0.023). Remarkably, PBMCs treated with IL-38 siRNA produced up to 28-fold more of the proinflammatory mediators IL-6, CCL2, and APRIL than did control siRNA-transfected cells upon stimulation with Toll-like receptor agonists. Similarly, in SLE patients, the antiinflammatory cytokine IL-10 was 5-fold more abundant when IL-38 was detectable. Conclusion. This is the first study of the function of endogenous IL-38, and the data suggest that IL-38 may be protective in SLE. A strong association between IL-38 and SLE severity suggests that IL-38 expression is driven by processes linked to SLE pathogenesis. Exploitation of the regulatory effects of IL-38 may represent a promising therapeutic strategy in SLE.